KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Exchange Rate Effect (2016 - 2025)

Travere Therapeutics' Exchange Rate Effect history spans 12 years, with the latest figure at -$413000.0 for Q4 2025.

  • For Q4 2025, Exchange Rate Effect rose 57.16% year-over-year to -$413000.0; the TTM value through Dec 2025 reached $2.3 million, up 350.93%, while the annual FY2025 figure was $2.3 million, 350.93% up from the prior year.
  • Exchange Rate Effect reached -$413000.0 in Q4 2025 per TVTX's latest filing, down from $207000.0 in the prior quarter.
  • In the past five years, Exchange Rate Effect ranged from a high of $1.9 million in Q2 2025 to a low of -$1.7 million in Q2 2022.
  • Average Exchange Rate Effect over 5 years is $113900.0, with a median of $53000.0 recorded in 2021.
  • Peak YoY movement for Exchange Rate Effect: tumbled 3085.71% in 2022, then skyrocketed 1888.07% in 2025.
  • A 5-year view of Exchange Rate Effect shows it stood at $1.7 million in 2021, then tumbled by 33.66% to $1.1 million in 2022, then grew by 7.89% to $1.2 million in 2023, then plummeted by 178.31% to -$964000.0 in 2024, then surged by 57.16% to -$413000.0 in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Exchange Rate Effect are -$413000.0 (Q4 2025), $207000.0 (Q3 2025), and $1.9 million (Q2 2025).